Syngeneic monoclonal anti-IgE antibodies are of value in studies of the suppression of IgE synthesis. Procedures are described here for the production of high titers of murine anti-IgE antibodies by initiating immunization in the perinatal period, before mice develop tolerance to their autologous IgE. This in turn facilitates the production of monoclonal anti-IgE antibodies. Properties of some of these mAbs are reported, including affinity, fine specificity and ability to bind to IgE on B lymphoma cells or mast cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0022-1759(95)00056-g | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biological Effects and Clinical Application of the Anti-Immunoglobulin E Antibody.
Int Arch Allergy Immunol
November 2024
Department of Dermatology and Venereology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
Background: Immunoglobulin E (IgE) plays a pivotal role in the pathogenesis of allergic diseases by engaging with FcεRI and FcεRII receptors, triggering allergic responses. The development of anti-IgE antibodies, such as omalizumab, has introduced a targeted approach to allergy treatment by neutralizing free IgE and dampening the allergic cascade.
Summary: This review synthesizes the current understanding of IgE's role in allergic diseases and evaluates the clinical utility of omalizumab.
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens.
Immunotherapy
December 2024
Allergy Research Unit, Kingston Health Sciences Center - KGH Site, Kingston, ON, Canada.
Article Synopsis
- * Nontraditional immunotherapy options, like sublingual and intralymphatic methods, are emerging as promising alternatives that could offer shorter treatment times and improved safety and effectiveness compared to traditional methods.
- * More research, including large-scale and long-term studies, is necessary to standardize treatment protocols and accurately compare the outcomes of these new therapies before they become widely adopted in clinical practice.
Allosteric inhibition of IgE-FcεRI interactions by simultaneous targeting of IgE F(ab')2 epitopes.
Commun Biol
August 2024
Atopy Research Center, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
Immunoglobulin E (IgE) plays pivotal roles in allergic diseases through interaction with a high-affinity receptor (FcεRI). We established that Fab fragments of anti-IgE antibodies (HMK-12 Fab) rapidly dissociate preformed IgE-FcεRI complexes in a temperature-dependent manner and inhibit IgE-mediated anaphylactic reactions, even after allergen challenge. X-ray crystallographic studies revealed that HMK-12 Fab interacts with each of two equivalent epitopes on the Cε2 homodimer domain involved in IgE F(ab')2.
View Article and Find Full Text PDFA Comparison of Natural and Therapeutic Anti-IgE Antibodies.
Antibodies (Basel)
July 2024
Department of Rheumatology and Immunology, University Hosptial of Bern, 3010 Bern, Switzerland.
Article Synopsis
- Immunoglobulin E (IgE) is crucial for fighting off parasites, toxins, and cancer but can cause allergic reactions like anaphylaxis when misregulated.
- Effector cells such as basophils and mast cells, which display IgE, initiate these reactions through degranulation when triggered by allergens.
- Therapeutic monoclonal antibodies like omalizumab are used to manage IgE-related conditions, and recent studies suggest naturally occurring anti-IgE autoantibodies may help regulate IgE activity, highlighting potential therapeutic insights.
An optimized method for IgE-mediated degranulation of human lung mast cells.
Front Immunol
June 2024
Division of Immunology and Allergy, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
Background: Mast cells are critically involved in IgE-mediated diseases, e.g., allergies and asthma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!